Oncimmune Regulatory News (ONC)

6th April 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Agreements signed with Roche and Cedars-Sinai to profile patients using Oncimmune's novel Infectious Disease panel

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that it has signed two separate agreements with Roche Pharmaceuticals ("Roche") and Cedars-Sinai Medical Center ("Cedars-Sinai"), in each case to use the Company's newly developed and proprietary Infectious Disease panel.

On 6 October 2020, Oncimmune announced the award of UK Government funding for the development and validation of an Infectious Disease NavigAID™ panel under the IMmunity Profiling of pAtients with COVID-19 for Therapy and Triage ("IMPACTT") programme. Utilising the data from this and other work, the Company's current SeroTag™ research panel has been tailored to predict COVID-19 disease severity and therapeutic response to the virus and the effectiveness of vaccines and other repurposed therapeutics as treatment against the disease. Both of these substantial new contracts will utilise this research tool to profile patient samples in search of immune related signatures in COVID-19 patients.

For Roche, Oncimmune will utilise its Infectious Disease panel to profile antibody and autoantibody responses in all patient samples from the Roche COVACTA trial, to look for immune signals of response, non-response and adverse events. The COVACTA trial was set up to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia. The contract also includes an option to extend to IgA and IgM antibody profiling which will substantially increase the value of the contract.

In October 2020, Oncimmune also announced that it had entered into an agreement with Cedars-Sinai in Los Angeles, a world-leading medical research organisation, to provide antibody profiling in COVID-19 samples as biomarkers for this disease. Following on from this first project, Cedars-Sinai has agreed to expand its collaborative COVID-19 programme to study a unique cohort of patients.

Dr Adam M Hill, CEO of Oncimmune said: "We are delighted to be strengthening our partnership with Roche and Cedars-Sinai through these two very important projects. As the world shifts its focus to recovering from the pandemic, we are seeing continued interest in Oncimmune's infectious disease offering. Today's announcement is further validation of the importance of our Infectious Disease panel in supporting both clinical research and the development of vaccines and therapeutics. We are also experiencing substantial interest in our immuno-oncology and autoimmune activities, which together with our infectious disease offering, provides us with confidence in the continued growth of ImmunoINSIGHTS."

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

About Oncimmune

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.

Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, and has a discovery research centre in Dortmund, Germany.

For more information, visit www.oncimmune.com

What is ImmunoINSIGHTS?

The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

What is NavigAID™?

Oncimmune's NavigAID arrays are thoroughly validated containing well defined antigen panels, largely encompassing markers of interest for each of the disease types being investigated.

Our portfolio of panels includes out-of-the-box NavigAID arrays for immuno-oncology and autoimmune diseases. These validated panels are frequently used as the starting point for collaborations with partners to add further markers of interest to their specific therapy and its specific indication.

What is SeroTag™?

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers can help stratify patients in multiple cancer indications and with different autoimmune diseases.

This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally invasive liquid biopsies. SeroTag analyses autoantibodies-some of the most stable analytes-and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.

The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune's NavigAID disease-specific stratification panels-precision medicine tools which are enabling patient and disease stratification and support therapeutic development.